CanSino Biologics, Inc. Class H (CJH) Stock Statistics & Valuation Metrics
Total Valuation
CanSino Biologics, Inc. Class H has a market cap or net worth of EUR 1.49B. The enterprise value is EUR 8.04B.
- Market Cap
- EUR 1.49B
- Enterprise Value
- EUR 8.04B
Share Statistics
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 132,670,900
- Owned by Insiders
- ―
- Owned by Institutions
- 7.45%
Financial Efficiency
CanSino Biologics, Inc. Class H’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is -1.76%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- -1.76%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 910.03K
- Profits Per Employee
- 23.94K
- Employee Count
- 1,134
- Asset Turnover
- 0.14
- Inventory Turnover
- 1.03
Valuation Ratios
The current PE Ratio of CanSino Biologics, Inc. Class H is 575.13. CanSino Biologics, Inc. Class H’s PEG ratio is 6.14.
- PE Ratio
- 575.13
- PS Ratio
- 9.60
- PB Ratio
- 3.26
- Price to FCF
- -198.25
- Price to Operating Cash Flow
- 166.60
- PEG Ratio
- 6.14
Income Statement
In the last 12 months, CanSino Biologics, Inc. Class H had revenue of 1.03B and earned 27.15M in profits. Earnings per share was 0.11.
- Revenue
- 1.03B
- Gross Profit
- 681.82M
- Operating Income
- -113.12M
- Pretax Income
- 21.18M
- Net Income
- 27.15M
- EBITDA
- 60.98M
- Earnings Per Share (EPS)
- 0.11
Cash Flow
In the last 12 months, operating cash flow was 95.95M and capital expenditures -159.52M, giving a free cash flow of -63.56M billion.
- Operating Cash Flow
- 95.95M
- Free Cash Flow
- -63.56M
- Free Cash Flow per Share
- -0.25
Dividends & Yields
CanSino Biologics, Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.50%
- Earnings Yield
- 0.18%
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- -43.96%
- 50-Day Moving Average
- 3.31
- 200-Day Moving Average
- 3.17
- Relative Strength Index (RSI)
- 36.53
- Average Volume (3m)
- 651
Important Dates
CanSino Biologics, Inc. Class H upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
CanSino Biologics, Inc. Class H as a current ratio of 3.55, with Debt / Equity ratio of 26.01%
- Current Ratio
- 3.55
- Quick Ratio
- 3.23
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 0.87
- Interest Coverage Ratio
- -2.03
Taxes
In the past 12 months, CanSino Biologics, Inc. Class H has paid -5.98M in taxes.
- Income Tax
- -5.98M
- Effective Tax Rate
- -0.28
Enterprise Valuation
CanSino Biologics, Inc. Class H EV to EBITDA ratio is 103.14, with an EV/FCF ratio of -195.00.
- EV to Sales
- 9.45
- EV to EBITDA
- 103.14
- EV to Free Cash Flow
- -195.00
- EV to Operating Cash Flow
- 121.12
Balance Sheet
CanSino Biologics, Inc. Class H has EUR 1.77B in cash and marketable securities with EUR 929.08M in debt, giving a net cash position of EUR 845.50M billion.
- Cash & Marketable Securities
- EUR 1.77B
- Total Debt
- EUR 929.08M
- Net Cash
- EUR 845.50M
- Net Cash Per Share
- EUR 6.37
- Tangible Book Value Per Share
- EUR 19.01
Margins
Gross margin is 71.84%, with operating margin of -0.78%, and net profit margin of 2.36%.
- Gross Margin
- 71.84%
- Operating Margin
- -0.78%
- Pretax Margin
- 2.88%
- Net Profit Margin
- 2.36%
- EBITDA Margin
- 9.16%
- EBIT Margin
- -2.35%
Analyst Forecast
The average price target for CanSino Biologics, Inc. Class H is EUR 5.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.67
- Price Target Upside
- 95.41% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 30.09%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- ―
